<DOC>
	<DOCNO>NCT00065468</DOCNO>
	<brief_summary>The primary objective study efficacy . The primary efficacy endpoint study comparison overall survival subject treat CCI-779 [ Temsirolimus ] , administer intravenously [ IV ] weekly combination CCI-779 , administer IV weekly Interferon Alfa [ IFN alfa ] subcutaneously [ SC ] three time per week [ TIW ] , compare overall survival subject treat IFN alfa ( SC TIW ) alone , poor-prognosis subject advance RCC .</brief_summary>
	<brief_title>Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>This study conduct subject histologically confirm , advance ( stage IV recurrent disease ) RCC receive prior systemic therapy disease , Subjects central nervous system ( CNS ) metastases Prior anticancer therapy RCC Prior investigational therapy/agents within 4 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
	<keyword>Kidney Cancer</keyword>
</DOC>